



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. Timothy Greenamyre, et al.

APPLICATION SERIAL NO.: 09/148,973

: Examiner: Hsu, G.

FILING DATE: September 4, 1998

: Group Art Unit: 1627

TITLE: METHODS OF ADMINISTERING AN  
AMPA RECEPTOR ANTAGONIST TO  
TREAT DYSKINESIAS ASSOCIATED  
WITH DOPAMINE AGONIST THERAPY

Box CPA

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

COMMUNICATION

Applicants kindly request that the Examiner consider the remarks in the Communication filed in connection with the subject application January 4, 2001 in response to the June 20, 2000 final Office Action. Applicants are attaching hereto an Information Disclosure Statement, including form PTO-FB-A820, listing the reference pages submitted with applicants' January 4, 2001 Communication. It is kindly requested that the Examiner initial on the form PTO-FB-A820 after considering the listed reference pages.

It is noted that claims 1-8 remain pending in the subject application. In the January 24, 2001 Advisory Action issued in connection with the subject application, the Examiner stated that newly presented generic claim 9 raises new issues. However, applicants did not present claim 9 in their January 4, 2001 Communication and applicants are not presenting claim 9 in the instant Communication.

It is believed that upon consideration of the remarks in the January 4, 2001 Communication and the reference forwarded therewith and cited in the attached Information Disclosure Statement, the Examiner will concur that the current claims 1-8 are directed to novel and unobvious subject matter.

If a telephone interview would be of assistance in advancing the prosecution of the subject application, the Examiner is kindly invited to telephone applicants' undersigned attorney at the telephone number provided below.

No fee, other than the fee for the one month extension authorized in the petition filed currently herewith and the fee for filing a CPA authorized in the Request Transmittal herewith, is believed necessary for filing the subject Communication. However, should any additional fee be determined necessary, authorization is given to charge such fee to Deposit Account No. 16-1445.

Respectfully submitted,

Date: March 20, 2001

  
Kristina L. Konstas  
Attorney for Applicant(s)  
Reg. No. 37,864

Pfizer Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 733-6380

EXPRESS MAIL NO. EL162815048US